For research use only. Not for therapeutic Use.
BV02 is a potent 4-3-3 PPI (14-3-3 protein–protein interaction) inhibitor. BV02 shows cytotoxicity for hematopoietic cells expressing the IM (imatinib mesylate)-sensitive wild type Bcr-Abl and the IM-resistant T315I mutation. BV02 has the potential for the research of chronic myeloid leukemia[1][2].
| Catalog Number | I023876 |
| CAS Number | 292870-53-2 |
| Synonyms | 2-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-1,3-dioxoisoindole-5-carboxylic acid |
| Molecular Formula | C20H15N3O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C20H15N3O5/c1-11-16(19(26)23(21(11)2)13-6-4-3-5-7-13)22-17(24)14-9-8-12(20(27)28)10-15(14)18(22)25/h3-10H,1-2H3,(H,27,28) |
| InChIKey | ZFYSDSINNOLWGO-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N3C(=O)C4=C(C3=O)C=C(C=C4)C(=O)O |
| Reference | [1]. Valensin D, et al. Molecular insights to the bioactive form of BV02, a reference inhibitor of 14-3-3σ protein-protein interactions. Bioorg Med Chem Lett. 2016 Feb 1;26(3):894-898. [2]. Mancini M, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther. 2011 Mar;336(3):596-604. |
